Clinical trial · Interventional
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
Phase II Clinical Study of IMM2510 for Injection Combined With IMM27M for Injection in Advanced Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase 2, open-label, multicenter,study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant - Page 1 of 5 - protein) combine with IMM27M(Anti-CTLA-4 Humanized monoclonal antibody) in patients with advanced hepatocellular carcinoma who not have received the treatment for aHCC in past
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HCC - Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IMM2510, IMM27M | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Participants will receive IMM2510 20.0 mg/kg(Q2W), will receive IMM27M 1.0 mg/kg (Q8W)
- interventionNames
- Drug: IMM2510, IMM27M
Primary outcomes (1)
- measure
- Objective Response Rate (ORR)
- timeFrame
- From date of first dose until the date of first documented progression, death from any cause, loss of follow-up, withdrawal of informed consent, or study termination by the sponsor, whichever came first, assessed up to approximately 2 years
Secondary outcomes (7)
- measure
- Disease Control Rate(DCR)
- timeFrame
- From date of first dose until the date of first documented progression, death from any cause, loss of follow-up, withdrawal of informed consent, or study termination by the sponsor, whichever came first, assessed up to approximately 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: Participant has provided informed consent prior to initiation of any study specific activities/procedures. * Age greater than or equal to 18 years old and ≤ 75 years old at the same time of signing the informed consent. * Histologically or cytologically confirmed for HCC * Eastern Cooperative Oncology Group (ECOG) 0 to 1. * Adequate organ function as defined in protocol. Exclusion Criteria: * History of other malignancy within the past 5 years with exceptions. * Systemic chemotherapy was administered within 4 weeks prior to the first administration. * Activated symptomatic brain metastases and leptomeningeal disease. * History of hepatic encephalopathy disease in past 12 months. * Participants with symptoms and/or clinical signs and/or uncontrolled active systemic infection within 14 days prior to the first dose of study treatment. Participant has known active infection requiring parenteral antibiotic treatment.
References
Publications (0)
Data not yet available